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ABSTRACT  
Background 
An accurate detection of individuals at clinical high risk of psychosis (CHR hereafter) is a 
prerequisite for effective preventative treatments. Several prognostic psychometric interviews 
are available, but their comprehensive prognostic accuracy is unknown.  
Methods 
Prognostic accuracy meta-analysis of psychometric interviews was employed to examine 
referrals to high risk services. Index test was the CHR diagnostic psychometric instrument 
used to identify subjects with (CHR+) and without CHR (CHR-). The reference index was 
psychosis onset over time in both CHR+ and CHR-. Data were analysed with MIDAS 
(STATA13). Area Under the Curve, Summary Receiver Operating Characteristics curves, 
quality assessment, likelihood ratios, Fagan’s nomogram and probability modified plots were 
computed. 
Results 
Eleven independent studies were included with a total of 2519 help-seeking, predominately 
adult  subjects (CHR+: n = 1359; CHR-: n= 1160) referred to high risk services. Mean 
follow-up was 38 months. The AUC was excellent (0.90; 95%CI: 0.87 - 0.93), and 
comparable to other tests in preventative medicine, suggesting clinical utility in subjects 
referred to high risk services. Meta-regression analyses revealed an effect for exposure to 
antipsychotics and no effects for type of instrument, age, gender, follow-up time, sample size, 
quality assessment, proportion of CHR+ in the total sample. Fagan’s nomogram indicated a 
low positive predictive value (5.74%) in the general non-help seeking population. 
Conclusions 
Albeit the clear need to further improve prediction of psychosis, these findings support the 
use of psychometric prognostic interviews for CHR as clinical tool for an indicated 
prevention in subjects seeking help at high risk services worldwide. 
 
INTRODUCTION 
Treatments for psychosis have been in wide use for nearly half a century, yet there is little 
evidence that they have substantially improved outcomes1. Therefore, indicated preventative 
treatment in psychosis is the main paradigm yielding new hope for impacting the course of 
psychosis2. However, preventative treatment of psychosis requires first an accurate diagnosis 
of individuals at clinical high risk (CHR hereafter) that relies on the use of accurate 
prognostic tools to detect psychosis as early as possible so that its progress can be arrested 
and, if possible, reversed. 	  
Prognostic testing is commonly used in preventative medicine3. While a screening test should 
identify all individuals who may develop the disease4, a prognostic test is used to predict the 
presence or absence of the future disease when a patient shows some heralding signs or 
symptoms of the disease. Examples of predictive testing in somatic medicine include fasting 
glucose and oral glucose tolerance test and glycated haemoglobin to detect subjects at high 
risk for diabetes (prediabetes or intermediate hyperglycaemia)5. Prediabetes closely resembles 
the CHR state in that only about 5–10% of people per year will progress to diabetes, with the 
same proportion converting back to normoglycaemia5. Since no biological test such as those 
used to detect prediabetes are available in clinical psychiatry6, for an indicated prevention of 
psychosis, prognostic testing is usually accomplished by administration of specific 
psychometric interviews, which assess validated CHR criteria7. These instruments include the 
Comprehensive Assessment of At Risk Mental State (CAARMS)8, 9, the Structured Interview 
for Psychosis-Risk Syndrome (SIPS)10 and the Basel Screening Instrument for Psychosis 
(BSIP)11 for the assessment of ‘ultra-high risk’ (UHR) criteria12, and the Bonn Scale for the 
Assessment of Basic Symptoms (BSABS)13 and, developed from it, the Schizophrenia 
Proneness Instruments (Adult Version, SPI-A14, and Child & Youth version, SPI-CY15) for 
the assessment of basic symptom (BS) criteria16. The UHR criteria include attenuated 
psychotic symptoms (APS), brief limited intermittent psychotic symptoms (BLIPS) and trait 
vulnerability plus a marked decline in psychosocial functioning (Genetic Risk and Functional 
Deterioration Syndrome: GRFD). The two partially overlapping BS criteria rely on 
subjectively experienced disturbances of perception, thinking, language and attention17. 	  
These CHR instruments show excellent reliability in trained raters: the overall inter-rater 
agreement for the SIPS was 0.9518, for the CAARMS 0.8512 and for the SPI-A 0.9119. Yet, 
their prognostic accuracy is still uncertain. For an ideal instrument, all subjects actually about 
to develop psychosis should be classified as “at risk” (CHR+) while those suffering from 
other complaints not leading to frank psychosis should be classified as “not at risk” (CHR-). 
This prognostic accuracy of a test can be quantified by different measures: Sensitivity (Se), 
Specificity (Sp), Summary Receiver-Operating-Characteristic (SROC) curves or Area Under 
the Curve (AUC); whose evaluation requires follow-up not only of CHR+ but also of CHR- 
subjects. So far, no robust meta-analysis has addressed the consistency and magnitude of the 
prognostic accuracy of psychometric CHR testing; and the few available studies reported 
inconsistent prognostic accuracy findings20 21. Because of this, the overall clinical utility (i.e. 
predictive value) of psychometric interviews in help-seeking and non help-seeking subjects is 
still unknown. Indeed, predictive values are not fixed indicators of a test performance but are 
affected by the prevalence of the condition4. Within help-seeking CHR+ samples, the ability 
of above psychometric instruments used towards identification of true positives is 
accumulating to 29% at 2-year follow-up22, 23 – a finding comparable to other preventative 
approaches in medicine24. Conversely, the predictive value and potential clinical utility of 
these instruments in samples with a lower prevalence of the condition, such as the general 
population, still await results from follow-ups25-27. Similarly, the predictive value in other 
samples with a variable psychosis risk such as unselected psychiatric adolescents28, subjects 
accessing public treatment services, psychiatric patients in forensic units29, primary care 
patients, genetic high risk samples, prisoners, post-partum women, 22q11.2 deletion 
syndrome, users of high potency cannabis, military, black ethnic minorities, refugees, 
borderline personality disorders or epilepsy is still largely unknown. 
To overcome this lack of knowledge, we conducted the first robust meta-analysis to examine 
the consistency and magnitude of the prognostic accuracy of instruments used for psychosis 
prediction while at the same time investigating its potential clinical utility in help-seeking  
samples of high risk services, in the general population and across other groups.  
 
METHODS 
Search strategy 
Two investigators (MC, GR) conducted a two-step literature search. At a first step, the Web 
of KnowledgeSM database by Thomson Reuters® was searched, incorporating both the Web 
of ScienceSM and MEDLINE®. The search was extended until March 2015, including 
abstracts in English language only. The electronic research adopted several combinations of 
the following keywords: “at risk mental state”, “psychosis risk”, “prodrome”, “prodromal 
psychosis”, “ultra-high risk”, “high risk”, “help-seeking”, “diagnostic accuracy”, 
“sensitivity”, “specificity”, “psychosis prediction”, “psychosis onset” and name of the 
possible CHR assessment instruments. The second step involved the use of Scopus® to 
investigate citations of previous systematic reviews on transition outcomes in CHR subjects 
and a manual search of the reference lists of the retrieved articles. Articles identified through 
these two steps were then screened for the selection criteria on basis of abstract reading. The 
articles surviving this selection were assessed for eligibility on basis of full-text reading. To 
achieve a high standard of reporting, we adopted the MOOSE checklist30 (available from the 
authors on request). 
 
Selection criteria 
Studies were eligible for inclusion if the following criteria were fulfilled: (a) were original 
articles, written in English or in German; (b) have screened the same pool of referrals with an 
established CHR psychometric instrument (index test)7 (i.e. APS, BLIPS, GRFD or BS); (c) 
have followed up both CHR+ and CHR for psychosis onset (reference index) with established 
international diagnostic manuals (ICD/DSM); (d) have reported sufficient prognostic 
accuracy data. With respect to the latter point, when data were not directly presented they 
were indirectly extracted from associated data. Additionally, we contacted all corresponding 
authors to request additional data when needed.  
Exclusion criteria were: (a) abstracts, pilot datasets, reviews, articles in language other than 
English and German; (b) articles that were not interviewing the same pool of referrals or that 
used an external CHR- group of healthy controls; (c) articles with overlapping datasets. 
Specifically, in case of multiple publications deriving from the same study population, we 
selected the articles reporting the largest and most recent data set.  Literature search was 
summarized according to the PRISMA guidelines31. 
 
Recorded variables 
Data extraction was independently performed by two investigators (MC, GR): author, year of 
publication, characteristics of CHR samples (baseline sample sizes, mean age and age range, 
proportion of females), the CHR diagnostic instrument used, exposure to antipsychotics, 
diagnostic criteria used at follow-ups to assess the psychotic outcome, follow-up time, 
prognostic accuracy data (number of true and false positives, true and false negatives or 
associated data) and quality assessment conducted with the QUADAS checklist32. 
 
Statistical analysis 
The statistical analysis followed the Cochrane Guidelines for Systematic Reviews of 
Diagnostic Test Accuracy Version 1.033 and the Methods Guide for Authors of Systematic 
Reviews of Medical Tests by the Agency for Healthcare Research and Quality (chapter 8) 34. 
Briefly, evaluating test accuracy requires knowledge of two quantities, the test’s Se and Sp. 
Meta-analysis methods for diagnostic test accuracy thus have to deal with two summary 
statistics simultaneously rather than one33. Methods for undertaking analyses which account 
for both Se and Sp, the relationship between them, and the heterogeneity in test accuracy, 
require fitting advanced hierarchical random effects models33. 
For each study we constructed a two-by-two table, which included true positive, false-
positive, true-negative, and false-negative values. When studies reported different data at 
different follow-up time, we used data from the longest follow-up (please see below). The 
baseline sample size was conservatively used as the base reference to avoid a bias towards 
overly high transition risks at longer follow-ups and related higher drop-out rates of 
transition-negatives.  
Data were then analysed with MIDAS (Meta-analytical Integration of Diagnostic Accuracy 
Studies)35, a comprehensive program of statistical and graphical routines for undertaking 
meta-analysis of diagnostic/prognostic test performance in STATA 13 software. The index 
tests of CHR status (CHR+ or CHR-) and reference tests of transition to psychosis according 
to international diagnostic manuals (ICD/DSM as gold standard) were dichotomous. Primary 
data synthesis was performed within the bivariate mixed-effects regression framework for the 
logit transforms of Se and Sp35. In addition to accounting for study size, the bivariate model 
estimates and incorporates the intrinsic negative correlation that may arise between Se and Sp 
within studies (threshold effect)36 as a result of differences in the test threshold between 
studies37. The bivariate model allows for heterogeneity beyond chance as a result of clinical 
and methodological differences between studies37. We estimated the summary Se and Sp and 
the estimated hierarchical SROC curves33. A SROC graph across each predictor, with the y-
axis representing the predictor’s Se and the x-axis representing 1-specificity, was used to plot 
around the summary estimates a 95% confidence region and a 95% prediction region to 
illustrate the precision with which the summary values were estimated (confidence ellipse of 
a mean) and to show the amount of between-study variation (prediction ellipse; the likely 
range of values for a new study). We also estimated the AUC. Finally, for sensitivity analyses 
of the impact of follow-up times, supplementary analyses were conducted by grouping the 
data at each specific time point of 6, 12, 24 and ≥30 months.  
Heterogeneity across studies was assessed using the I2, with values of 25%, 50%, and 75% 
representing mild, moderate, and severe inconsistency, respectively38. Within MIDAS, forest 
plots and heterogeneity statistics can be created for each test performance parameter 
individually or may be displayed as paired plots. Sub-groups analyses and meta-regressions 
were used to examine the influence of CHR instruments used, mean age, gender (% of 
females), follow-up time, sample size, exposure to antipsychotics, and quality assessment 
(QUADAS) on meta-analytical estimates. To control for biases associated with imbalanced 
datasets39, we further tested the impact of the proportion of CHR+ in the overall samples (i.e. 
CHR+ and CHR-). The meta-regressions were used if there was substantial heterogeneity 
(I2>50%)40. Model diagnostic analyses included quantile plot of residual based goodness-of 
fit; Chi-squared probability plot of squared Mahalanobis distances for assessment of the 
bivariate normality assumption; spike plot for checking for particularly influential 
observations using Cook’s distance; a scatter plot for checking for outliers using standardized 
predicted random effects (standardized level-2 residuals)35. Sensitivity analyses (i.e. exclusion 
of outliers and rerunning of the model) were conducted to further explore heterogeneity. We 
did not test publication bias41, because no proven statistical method exists for this type of 
meta-analysis42.  
 
In a second step we employed the probability-modifying plot and the Fagan’s nomogram to 
estimate the clinical or patient-relevant utility of the CHR interview in subjects seeking help 
at early detection services, in the general population as well as in other samples (i.e. genetic 
high risk samples, prisoners, post-partum women, 22q11.2 deletion syndrome, users of high 
potency cannabis, military, black ethnic minorities, borderline personality disorders or 
unselected psychiatric samples). The clinical utility was evaluated using the positive and 
negative likelihood ratios (LR+ and LR-) to calculate post-test probability (PostTP) based on 
Bayes’ theorem as follows with pre-test probability (PrePT)= prevalence of condition in 
target population: PostTP = LR × PreTP/[(1  ̶  PreTP) + (PreTP  × LR)]35. Specifically, the 
probability-modifying plot35, is a graphical sensitivity analysis of the test’s predictive values 
across a baseline psychosis risk continuum in people seeking help at early detection services. 
It depicts separate curves for positive and negative tests and uses general summary statistics 
(i.e., unconditional positive and negative predictive values, NPV and PPV, which permit 
underlying psychosis risk heterogeneity) to evaluate the effect of the CHR assessment on 
predictive values43. The PreTP probability of psychosis risk in subjects seeking help at early 
detection services was computed in the current dataset as the proportion of subjects 
developing psychosis on the total baseline sample (CHR+ plus CHR-)35. Fagan’s nomogram, 
a two-dimensional graphical tool for estimating how much the result of a test changes the pre-
test probability that a patient will develop psychosis, was used to estimate the clinical value of 
psychometric CHR diagnostic interview in the general population and in the other samples. 
Again, the clinical value is calculated on the LR+ and LR- obtained from the current meta-
analysis44 and using the pre-test psychosis risk in the different samples as estimated from the 
available literature.  
Statistical tests were two-sided and statistical significance was defined as p-values <0.05. 
 
RESULTS 
Database 
The literature review (PRISMA flow-chart available from the authors upon request) produced 
11 independent studies that met the inclusion criteria, for a total of 2519 (CHR+: n=1359; 
CHR-: n=1160) subjects referred to high risk services (Table 1). Proportion of CHR+ in the 
total sample (CHR+ and CHR-) was 0.54 revealing an overall balanced dataset. Four studies 
employed the CAARMS, three the SIPS, one the BSIP, one the BSABS, and two both the 
SIPS and SPI-A. The mean follow-up time was 37.72 months (SD 27.81, median=33). 
QUADAS ratings ranged from 2.5 to 14 (equals highest possible score), main reasons for a 
non-optimal rating were (partial) exposure to antipsychotics and unsatisfactory reporting of 
results.  
 
*** TABLE 1 ABOUT HERE *** 
 
Prognostic accuracy of CHR interview 
Across the 11 studies interviewing help-seeking subjects for CHR symptoms, the summary 
meta-analytical estimate of Se and the AUC were outstanding, while the estimate of Sp was 
poor (Figure 1). There was moderate to substantial heterogeneity for Se (I2=51, p=0.02) and 
severe heterogeneity for Sp (I2=95, p<0.001), 17% of which was due to threshold effects. 
Sensitivity analyses revealed that the two studies with the highest proportion of CHR- in the 
total sample had the highest Sp45,	  46, while the two studies with the lowest proportion of CHR- 
had the lowest Sp47,	   48. However, meta-regression analyses showed that the proportion of 
CHR+ in the total sample had no impact on the overall AUC39. Across SIPS samples (n=5)47,	  
49-­‐51 Se was 0.96 (95%CI:  0.88–0.99) and Sp 0.39 (95%CI: 0.32–0.46). Across CAARMS 
samples (n=4)45,	  46,	  48,	  52 Se was 0.96 (95%CI: 0.82–0.99), Sp 0.56 (95%CI: 0.38-0.73). There 
were not enough data to perform subgroups meta-analyses in BSIP samples (n=1)11, 
BSABS/SPI-A samples (n=3)53 47, 51 and in samples combining the SIPS and SPI-A (n=1)47. 
Meta-regression analyses revealed no significant effects for mean age, gender, follow-up 
time, sample size and quality assessment (QUADAS), but there was a significant effect for 
exposure to antipsychotics at baseline (p=0.04). This effect was driven by a significant 
decrease of Se (0.94) in studies (n=5) where subjects were exposed to antipsychotics as 
compared to studies (n=6) were subjects were not exposed (Se=0.98). Model diagnostics 
revealed a good fit of the model and indicated that one study was close to the outlier 
threshold45. Sensitivity analyses confirmed a very good AUC (0.84) after this study was 
removed from the dataset. 
 
*** FIGURE 1 ABOUT HERE *** 
 
Finally, supplementary analyses were conducted grouping the available samples at specific 
time points of 6, 12, 24 and ≥ 30 months. The AUCs were outstanding at each time point: at 6 
months (7 samples, AUC=0.97, 95%CI: 0.95–0.98), at 12 months (6 samples, AUC=0.94, 
95%CI: 0.92–0.96), at 24 months (8 samples, AUC=0.94, 95%CI: 0.92–0.96), at more than 
30 months (7 samples, AUC=0.91, 95%CI: 0.88–0.93).  
 
Clinical utility of psychometric CHR interviews in subjects seeking help at high risk 
services 
The 38-month psychosis risk in the 2519 help-seeking subjects was 15% (95%CI: 0.9%-
24%). On the basis of this prior distribution, the continuous relationship between PreTP and 
PostTP probability is summarized in in Figure 2. Being CHR+ was associated with a 26% 
(95%CI: 23%-30%) risk of developing psychosis within 38 months, yet a small LR+ of just 
1.82 (95%CI: 1.52-2.18)54, while being CHR- was associated with a 1.56% (CI95%: 0.7%–
2.42%) risk of developing psychosis and a large LR- of 0.09 (CI95%: 0.04-0.18)54. 
 
*** FIGURE 2 ABOUT HERE *** 
 
Estimated clinical utility of psychometric CHR interviews in the general population and 
in other samples  
Based on a lifetime prevalence of all non-organic psychotic disorders of 3.27%60 and the 
above LRs, Fagan’s nomogram revealed only limited clinical utility for CHR instruments in 
the general population by estimating testing positive for CHR was associated with a 5.74% 
lifetime risk of developing psychosis, while testing negative was associated with hardly any 
such risk (0.26%).  
 
*** FIGURE 2 ABOUT HERE *** 
 
Corresponding figures for other clinical and non-clinical samples are displayed in Table 2. 
. 
*** TABLE 2 ABOUT HERE *** 
 
DISCUSSION  
This is the first study to present a robust and elaborated meta-analytical estimate of the 
prognostic accuracy of psychometric CHR interviews for psychosis prediction. Assessing 
help-seekers referred to a high risk service with a CHR interview generally revealed an 
excellent overall prognostic performance in terms of the AUC at three years (38 months) 
follow-up (values of 0.9-1.0 are considered outstanding, of 0.8-0.9 excellent and of 0.7-0.8 
acceptable55), which was comparable to other preventative approaches in medicine. However, 
excellent AUC values were mainly mediated by an excellent ability of the instruments to rule 
out psychosis (i.e., very satisfyingly low LR- and high Se), at an expense of their ability to 
rule in psychosis (i.e., unsatisfyingly low LR+ and only moderate overall Sp), which indicates 
some need to further improve prediction. Conversely, the clinical utility of current CHR 
instruments in non-help-seeking subjects in the general population was estimated to be low 
 
Our first aim was to investigate at meta-analytical level the overall prognostic accuracy of 
CHR instruments in determining the risk of developing psychosis at three years (38 months) 
in young help-seeking subjects referred to high risk services. We first estimated the AUC, 
which serves as a global measure of test performance and indicates the overall goodness of a 
diagnostic tests. Thereby, we adopted a robust methodological approach following 
international guidelines for diagnostic/prognostic accuracy meta-analysis, to avoid the serious 
flaws observed in a previous meta-analytical attempt, such as overlapping samples, missing 
studies and lack of control for several moderators56, 57. Our finding of consistent prognostic 
accuracy across CHR instruments is particularly important, given the significant differences 
of operationalization criteria58. This finding of a negligible role of the CHR assessment 
instrument (i.e. CAARMS vs SIPS) is in line with our previous meta-analysis which found no 
differences in pooled annual transition risks between these instruments22. This finding was 
also confirmed by a second independent meta-analysis by the EPA taskforce23. We further 
revealed that despite an excellent overall prognostic accuracy there is a need to specifically 
improve the ability to rule in subsequent psychosis, i.e., to improve LR+ and Sp, while 
preserving the outstanding ability to rule it out. This is particularly relevant given that 
interviewing subjects seeking help at high risk services is particularly difficult: these 
individuals are assumed to lay on an upper mid-range of a symptomatic continuum by 
showing mild and often infrequent symptoms of yet some clinical significance already25. 
However, differentiating between such gradual symptoms with specific tests or interviews is 
not a problem specific to psychosis prevention or other preventive approaches in psychiatry. 
For example in case of the at-risk state of diabetes, the WHO proposed the use of the term 
“intermediate hyperglycaemia” (i.e. pre-diabetes) to accurately reflect the observation that 
glucose is a continuous variable and that their defined categories are based on somewhat 
arbitrary decisions on where to draw a line between normality and abnormality59. Similarly to 
the different cut-offs and operationalization criteria used to identify CHR subjects, the 
definition of pre-diabetes is based on cut-off points for glucose5 to that there are different 
diagnostic operationalisations (e.g. by WHO and by the American Diabetes Association5). 
Furthermore, as for the CHR state7, progression to diabetes is not inevitable in pre-diabetes; 
some individuals, in the absence of any intervention may remain in that state or even revert to 
normoglycaemia5. Because of this, various risk assessment tools based on sociodemographic 
or questionnaire data are available to identify subjects with pre-diabetes, and their overall 
prognostic accuracy is comparable to our meta-analytical estimates such as the AUC=0.76 
reported for the Cambridge risk score60. More broadly, the overall prognostic accuracy of the 
CHR instruments was comparable if not superior to various other medical tests used for an 
indicated prevention (Table 3). However, it is important to highlight that the high AUC of 
CHR instruments is secondary to an accurate training of raters and on-going close supervision 
provided by expert clinicians7. Thus, the recent EPA guidance on the early detection of 
psychosis explicitly recommends their CHR assessment in specialized centres by well-trained 
raters and/or clinical supervision by such raters.23 
 
*** TABLE 3 ABOUT HERE *** 
 
The imbalance between an excellent Se (0.96) and an only modest Sp (0.47) may have some 
relevant clinical indications, when considering that we have selectively included only studies 
discriminating CHR+ from CHR- within the same pool of help-seeking subjects referred to 
early detection services. Since these patients were seeking help at or were subsequently 
referred to early detection services and frequently presented also with psychosocial and 
functional impairment61 and other non-psychotic symptoms62 and disorders63 (along with 
CHR symptoms), the use of CHR assessments should not be thought of as identifying and 
treating an unselected and asymptomatic group at risk of a poor outcome (universal 
prevention)64. Rather, the use of CHR assessment follows the approach of an indicated 
prevention, which is concerned with detecting a disease in its earliest stages, before frank 
symptoms appear, and with intervening to slow or stop its progression into the full-blown 
medical picture. Therefore, recent EPA guidance explicitly restricts CHR assessment to the 
clients of mental health services23. With regard to the potential CHR+ misdiagnosis of 
persons who do not in fact develop psychosis, or the potential CHR- misdiagnosis of persons 
who will develop psychosis, the low Sp suggests a stepped and multi-component strategy. In 
a first sensitivity-preserving step, CHR instruments could be used to rule out true negatives, 
i.e. subjects who are unlikely to develop psychosis. In a second step, additional clinical, 
neurocognitive, biological or combined models of risk stratification could be applied to the 
CHR+ group with the aim of increasing Sp and prognostic reliability. This would enable risk 
stratification and personalized treatments accordingly65, 66.  
 
We further estimated the clinical utility of CHR assessments in other clinical and non-clinical 
populations as clinical utility is affected by the underlying psychosis risk in a population. In 
particular, the conditional probability of a condition given a positive or negative test result, 
the so-called PPV and NPV values are critically important for clinical applications, and the 
PPV tends to be highest in settings with a high prevalence of the disorder4. We found that 
testing positive for CHR was associated with a 26% risk of developing psychosis within three 
years (38 months), a number comparable with our previous meta-analysis (95CI% 23 – 35)22 
of transition risks in CHR+ subjects. This was due to a small LR+ of 1.8254. We could also 
show here for the first time that being CHR- was associated with only a 1.56% risk of 
developing the illness, corresponding to a large LR- of 0.09. It is important to note that the 
PostTP, as estimated from the likelihood ratio and PreTP, is generally more accurate than if 
estimated from the PPV of the test. In fact, with help of these two measures (LR+ and LR-), it 
was possible to estimate the PostTP in different settings characterized by a variable PrePT of 
psychosis risk, which however will nevertheless require empirical studies. We clearly 
estimated for the first time a limited clinical utility of CHR interviews in the general 
population, revealing only small and inadequate PPV of 5.74%. Our estimate of limited 
clinical utility is in line with meta-analytical results indicating that self-reported psychotic-
like experiences in the young non help-seeking general population are associated with a 
negligible risk of transitioning to psychotic disorders over time67. Yet, as self-reported 
psychotic experiences are only a poor estimate of clinician-assessed CHR symptoms, these 
findings might not reflect on the true predictive power of CHR criteria in the 
community{Schultze-Lutter, 2014 #248}. Similarly, it appears there is no scope to assess 
psychometric CHR interviews in unselected psychiatric adolescent samples, patients 
accessing public treatment or primary care services, patients admitted to forensic units, post-
partum women, ethnic minorities, military, refugees, patients with epilepsy and prisoners. The 
latter finding is in line with a recent study indicating that the CHR state does not predict 
psychosis in adolescent delinquent samples29. Conversely, our estimates provide some 
support for the clinical utility of CHR assessments in subjects with two psychotic relatives, in 
patients with 22q11.2 deletion syndrome and in subjects using high potency cannabis, as well 
as for preventative trials already proposed in some of these clinical samples68. The additional 
novel finding is that our probability-modifying plot allows future power calculation studies in 
variable samples characterized by an underlying variable psychosis risk that is ranging from 0 
to 1. For example, with our plot available, the researchers may draw a vertical line from the 
selected pre-test probability of the sample to the appropriate likelihood ratio line and then 
reads the post-test probability off the vertical scale.  
 
Some limitations should be acknowledged. First, because of limited statistical power, we 
were unable to directly compare the prognostic accuracy of different psychometric 
instruments. However, subgroups analyses revealed comparable SIPS vs CAARMS AUCs. 
Furthermore, two independent meta-analyses22, 23 did not reveal any significant impact of the 
type of psychometric instrument employed on risk estimates. Also, we were unable explain 
all the observed heterogeneity across individual studies. However, some of this was explained 
by threshold effects and by the effect of antipsychotics exposure on Se. An effect of age, with 
lower transition risks in younger CHR+ subjects was observed in our first meta-analysis22 and 
recently confirmed in another re-analysis23. Such an age effect might have missed in our 
analyses, as only the by far smallest of the included studies with an only 6-month follow-up58 
was on minors only. Furthermore, the individual studies included here varied with respect to 
follow-up time, however, meta-regression did not reveal any significant effect. We 
additionally conducted supplementary analyses at each specific time points, and these 
analyses confirmed exceptional AUCs. Furthermore, there is new meta-analytical evidence 
that, in UHR samples, transition to psychosis is most likely to occur within the first 2 years 
after presentation to clinical services with a stable plateau after 36 months69. Since our mean 
follow-up time (38 months) falls in this plateau period, follow-up had no significant impact 
on the meta-analytical estimates across samples mainly at risk for UHR criteria. 
 
CONCLUSIONS 
The current prognostic accuracy meta-analysis indicated that currently used interviews for 
psychosis prediction have an excellent overall prognostic performance. This supports their 
use as clinical tool for an indicated prevention in subject seeking help at mental health 
services worldwide, provided raters have undergone adequate training, while discouraging 
their use for prevention in non-help-seeking subjects in the general population. 
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Table 1. Independent studies included in the meta-analysis (studies n=11, subjects n=2519; CHR+: 
n=1359, CHR-: n= 1160) 
Study	  	   QUADAS	  score	  
(14=max.);	  
exposure	  to	  
antipsychotics	  
at	  baseline	  	  
Predictor	  
(Index	  test)	  
Psychosis	  
diagnosis	  
(Reference	  
standard)	  
Age	  
(mean±SD,	  
range)	  
Gender	  
(%	  
females)	  
Follow-­‐
up	  
(months)	  
CHR+	  
(baseline)	  
CHR-­‐
(baseline)	  
1.	  
Klosterkötter,	  
et	  al.	  200153	  (a)	  
14;	  
NO	  
BSABS	  (BS)	   DSM-­‐IV	   29.3±10.0	  
(15-­‐53)	  
47.5	   0,	  ≥30	  	   110	   50	  
2.	  Yung,	  et	  al.	  
200846	  
12;	  
YES	  (Na)	  
CAARMS,	  
before	  2006	  
(UHR)	  
CAARMS	   18.1	  	  
(15-­‐24)	  
51.0	   0,	  6	  (b),	  
24	  
119	   173	  
3.	  Riecher-­‐
Rössler,	  et	  al.	  
200811	  
13.5;	  
NO	  	  
BSIP	  (UHR	  
plus	  4th	  
criterion)	  
BPRS	   26.8±8.9	  
(18-­‐60)	  
41.4(c)	   0,	  6,	  12,	  
24,	  ≥30	  	  
58	   32	  
4.	  Woods,	  et	  al.	  
2009	  (NAPL-­‐
1)49(d)	  
13.5;	  
YES	  (11.6%)	  
SIPS	  (UHR)	   DSM-­‐IV	  or	  
medical	  
records	  
17.8±4.4	  
(12-­‐36)	  
39.5	   0,	  6,	  12,	  
24	  	  
259	   111	  
5.	  Woods,	  et	  al.	  
2009	  
(PREDICT)49(d)	  
13.5;	  
YES	  (1.8%)	  
SIPS	  (UHR)	   DSM-­‐IV	   19.76±4.5	  
(12-­‐31)	  
47.8	   0,	  6,	  12,	  
24	  	  
172	   100	  
6.	  Liu,	  et	  al.	  
201150	  
2.5;	  
YES	  (79.7%)(c)	  
SIPS	  (UHR)	   DSM-­‐IV	   21.4±4.0	  
(16-­‐24)	  
47.7	   0,	  24	   59	   48	  
7.	  Simon,	  et	  al.	  
201251	  
6;	  
NO	  
SIPS	  /	  SPI-­‐A	  
(e)	  (BS	  /	  
UHR)	  
DSM-­‐IV	   21.0	  
(14-­‐40)	  
32.4	   0,	  12,	  24	   99	   49	  
8.	  Lee,	  et	  al.	  
201345(d)	  
13;	  
NO	  
CAARMS	  
before	  2006	  
(UHR)	  
DSM-­‐IV	   21.6±3.5	  
(14-­‐29)	  
39.9	   0,	  6,	  12,	  
24,	  ≥30	  
173	   494	  
9.	  Schultze-­‐
Lutter,	  et	  al.	  
201447	  
13;	  
YES	  (13.8%)	  
SPI-­‐A	  /	  SIPS	  
(e)	  (BS	  /	  
UHR)	  
DSM-­‐IV	   24.9±6.0	  
(15-­‐39)	  
37.0	   0,	  6,	  12,	  
24,	  ≥30	  	  
194	   52	  
10.	  Kotlicka-­‐
Antczak	  et	  al	  
201448(d)	  
11.5	  
YES	  (10.2%)	  
CAARMS	  
(UHR)	  
	  	  	  	  	  ICD-­‐10	   19.05±3.6	  
(15-­‐29)	  
51.1	  (c)	   ≥30	  	   94	   33	  
11.	  Spada,	  et	  
al.	  201552	  
11;	  
NO	  
CAARMS	  
(UHR)	  
DSM-­‐IV	   15.8±1.7	  
(12-­‐17)	  
47.5	   0,	  6	   22	   18	  
UHR, Ultra High Risk; BS, Basic Symptoms, BSABS, Bonn Scale for the Assessment of Basic Symptoms; BPRS, 
Brief Psychiatric Rating Scale; BSIP, Basel Screening Instrument for Psychosis; CAARMS, Comprehensive 
Assessment of At Risk Mental State; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders; SIPS, 
Structured Interview for Prodromal Syndromes; SPI-A, Schizophrenia Proneness Instrument; Na, not available; a) at 
least 1 BS; b) 6 months data reported in Yung et al 200670; c) CHR+ only; d) updated follow-up data provided by the 
authors; e) different combinations of SPI-A and SIPS criteria reported in this article. 
  
Figure 1. Meta-analytical Summary Receiver Operating Characteristics (SROC) curve of CHR 
instruments for psychosis onset in 2519 help-seekers at high risk services reported in 11 studies 
(follow-up 38 months). Legend: Se, sensitivity; Sp, specificity; AUC, area under the curve; 1 
Klosterkötter, et al. 200153 ; 2 Yung, et al. 200846; 3 Riecher-Rössler, et al. 200811; 4 Woods 
(NAPLS-1), et al. 200949; 5 Woods (PREDICT), et al. 200949, 6 Liu, et al. 201150; 7 Simon, et al. 
201251; 8 Lee, et al. 201345; 9 Schultze-Lutter, et al. 201447; 10. Kotlicka-Antczak et al 201448, 11 
Spada, et al. 201552. 
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Figure 2. Meta analytical probability modifying plot for illustration of the relationship between PerTP 
(9% to 24% psychosis risk at 38 months in subjects seeking help at early detection services) and 
PostTP (psychosis risk at 38 months in help-seeking subjects based on CHR instruments) computed as 
the likelihood of a positive (above diagonal line; LR+) or negative (below diagonal line, LR-) test 
result over the 0-1 range of PreTP.  
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Figure 3. Fagan’s nomogram illustrating the meta-analytical (subjects n=2519) clinical value (post-
test probability) of psychometric CHR interview in the general population in order to predict 38 
months risk of psychosis, given an assumed psychosis risk (pre-test probability) of 3.27%, as 
reported in a nationally representative sample (n= 8028) of the general population subjects of age 
30-44 year 71. 
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Prior Prob (%) =     3.27
LR_Positive =     1.8
Post_Prob_Pos (%) =    5.74
LR_Negative =  0.08
Post_Prob_Neg (%) =     0.26
Table 2. Estimated clinical utility of CHR instruments for psychosis prediction in different populations 
Sample Psychosis risk Positive Test Result Negative Test Result 
1 Unselected psychiatric adolescent samples 3.13%28 (12mo) 3.13% 0.29% 
2 Subjects in contact with public treatment services 0.35%72 (lifetime) 0.63% <0.001% 
3 Psychiatric patients in forensic units 74%73 (lifetime) 83.38% 20.39% 
4 Primary care patients 0.045%74 (per year) <0.001% <0.001% 
5 Prisoners 3.90% 75 (lifetime) 6.87% 0.36% 
6 Post-partum women 4%76 (12mo) 7.04% 0.37% 
7 22q11.2 deletion syndrome 16% 77 (48mo) 25.74% 1.68% 
8 Familial risk for psychosis 12% 78 (30mo) 19.88% 1.21% 
9 Users of high potency cannabis 24% 79 (lifetime) 36.49% 2.76% 
10 Military 0.014% 80 (per year) <0.001% <0.001% 
11 Black ethnic minority 1.45 % 81 (lifetime) 2.60% 0.13% 
12 Refugees 3.3%82 (lifetime) 5.84% 0.31% 
13 Epilepsy 5.6%83 (lifetime) 9.74% 0.53% 
1. Unselected sample of adolescent psychiatric patients (n=161); 
2. National psychosis survey in representative sample of adults with psychotic disorders in contact with public treatment services 
(n=1642); 
3. Population based consecutive cohort of forensic psychiatric patients (n=125) 
4. Longitudinal patient records from a national primary care database (n=4164794) 
5. Prisoners (n=33 588) in unselected prison samples worldwide assessed;  
6. Past-year pregnant and postpartum women (n=14549) in the United States;  
7. Children and young adults (n=125) with 22q11.2 deletion syndrome;  
8. Young adults (n=163) with two relatives with schizophrenia;  
9. Patients with first-episode psychosis (n=470) and matched population controls (n=370);  
10. A 2000-2009 sample of US military (n=1976) admitted with a first episode of schizophrenia;  
11. UK individuals (n=549) of black ethnic minority background;  
12. Randomly selected participants screened by household representative (n = 748) and individual (n = 315) interviews 
13. Meta-analysis of 58 studies reporting risk of psychosis in patients with epilepsy 
Table 3. Prognostic accuracy of indicated prevention tests in clinical medicine 
At-risk population Outcome Diagnostic test Sensitivity 
(follow-up) 
Specificity 
(follow-up) 
AUC 
(follow-up) 
Patients presenting for CHR 
evaluation 
Psychosis CHR interview 0.96 
(2y) 
0.47 
(2y) 
0.89 
(2y) 
Men at risk for prostate cancera 
 
Prostate cancer PSA   0.6984 
(5y) 
0.8984 
(5y) 
0.8885 
(5y) 
Men at risk for colorectal cancer Colorectal cancer Risk prediction modelf Na† 
(5y) 
Na 
 (5y) 
0.8086 
(5y) 
Women at risk for colorectal cancer Colorectal cancer Risk prediction modelg Na 
 (5y) 
Na 
 (5y) 
0.7386 
(5y) 
Patients with transient ischemic attack Stroke ABCD2 Scorej 0.5787 
(30 days) 
0.3287 
(30 days) 
0.7288 
(7 days) 
Patients with stable coronary disease Coronary eventh Framingham Risk Scorei 
+  
number of diseased 
vessels 
Na 
(8.5y) 
Na 
 (8.5y) 
0.6789 
(8.5y) 
Prediabetesk Diabetes 30-min plasma glucose 0.9190 
(9y) 
0.3990 
(9y) 
0.6790 
(9y) 
Mild cognitive impairment Alzheimer’s disease ADAS-cog subscalel 0.62 91 
(1y) 
0.7391 
(1y) 
0.6791 
(1y) 
Women at risk for breast cancerc ERd- positive invasive breast 
cancer 
Gail modele 0.5092 
(5y) 
0.6592 
(5Y) 
0.6092 
(5y) 
* AUC, Area Under the Curve;  
†Na, Not Available. 
 a Age: 55-70; b PSA, Prostate-Specific Antigen; c Postmenopausal women, age: 50-79; d ER, Estrogen Receptor; e Age, ethnicity, age at menarche, age of the mother at the birth of 
her first live child, number of first-degree relatives with breast cancer (0, 1 or > 1), number of previous breast biopsy examinations (0, 1 or >1), and the presence or absence of 
atypical hyperplasia in the biopsy specimen; f Age, height, family history for cancer, BMI, and amount of alcohol consumed; g Age, height, family history of cancer, fasting glucose, 
meat consumption frequency; h Cardiac death, non-fatal myocardial infarction or unstable angina pectoris requiring unplanned coronary revascularization; i Age (≥45 years for men, 
≥55 years for women), hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or use of antihypertensive medication), smoking, diabetes, 
elevated cholesterol (cholesterol ≥240 mg/dL or LDL-C ≥160 mg/dL), and HDL-C <35 mg/dL; j Age≥60, hypertension (systolic blood pressure ≥140 mm Hg, diastolic blood pressure 
≥90 mm Hg), clinical features (unilateral weakness, speech impairment), symptom duration (greater than 60 min, 10-59 minutes), diabetes; k Impaired Fasting Glucose (IFG), 
fasting plasma glucose levels of 100–125 mg/dL, or Impaired Glucose Tolerance (IGT), 2-h PG 140-199 mg/dL, or Combined Glucose Intolerance (CGI), or HbA1c 5.7-6.4% 
(American Diabetes Association 2010); l Alzheimer Disease Assessment Scale-cognitive part. 
